Brown Brothers Harriman & Co’s Ligand Pharmaceuticals LGND Stock Holding History

Brown Brothers Harriman & Co’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$17.7K	Hold	56	–	–	﹤0.01%	1316
2026 Q1	$11.2K	Buy	56 +10	+22%	+$1.98K	﹤0.01%	1336
2025 Q4	$8.7K	Buy	+46	New	+$8.84K	﹤0.01%	1371
2025 Q1	–	Sell	-48	Closed	-$5.14K	–	1398
2024 Q4	$5.14K	Hold	48	–	–	﹤0.01%	1227
2024 Q3	$4.8K	Buy	+48	New	+$4.83K	﹤0.01%	1159
2020 Q1	–	Sell	-462	Closed	-$30K	–	1211
2019 Q4	$30K	Buy	+462	New	+$30.9K	﹤0.01%	742
2018 Q1	–	Sell	-236	Closed	-$20K	–	984
2017 Q4	$20K	Buy	+236	New	+$20.5K	﹤0.01%	648

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Brown Brothers Harriman & Co's LGND Position: Q2 2026 in Review

Brown Brothers Harriman & Co held its Ligand Pharmaceuticals (LGND) position steady in Q2 2026 at 56 shares worth $17.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1316.

Brown Brothers Harriman & Co first reported a position in LGND in Q4 2017 and has held it in 7 quarters since. The position peaked at $30K in Q4 2019. 415 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Brown Brothers Harriman & Co held 56 shares of Ligand Pharmaceuticals worth $17.7K as of Q2 2026.
Brown Brothers Harriman & Co left its Ligand Pharmaceuticals share count unchanged in Q2 2026.
Ligand Pharmaceuticals made up ﹤0.01% of Brown Brothers Harriman & Co's portfolio in Q2 2026, its #1316 holding.
Brown Brothers Harriman & Co first reported a position in Ligand Pharmaceuticals in Q4 2017 and has held it in 7 quarters since.
Brown Brothers Harriman & Co's Ligand Pharmaceuticals position peaked at $30K in Q4 2019.
415 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Brown Brothers Harriman & Co's 13F filing for Q2 2026, filed 12 Aug 2026.